Liang Lu

This inventor holds 33 USPTO granted patents and 18 published patent applications and 13 EPO patents, primarily in FGFR Inhibitors. Top assignees: Incyte Corporation, Incyte Holdings Corporation, Prelude Therapeutics Incorporated. Active years: 2016-2026.

USPTO Granted Patents = 33 (Patent Applications = 18)

% Patents Active = 97.0

EPO Patents = 13 (Patent Applications = 15)

Average Co-Inventor Count = 5.0

ph-index = 18

Forward Citations = 650(Granted Patents)

Location History:

Hockessin, DE (2016)
Hockessin, DE (US) (2017 - 2023)
Wilmington, DE (US) (2018 - 2023)

Company Filing History:

Incyte Holdings Corporation

patents

3 out of 18

Prelude Therapeutics Incorporated

patents

4. 1 out of 1

Prelude Therapeutis Incorporated

patent

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

FGFR Inhibitors

CDK Inhibitors

Immunomodulators

Tricyclic Compounds

Bicyclic Heterocycles

LSD1 Inhibitors

Pharmaceuticals

Heterocyclic Compounds

Targeting Compounds

Methods of Use

Compounds

Drug Discovery

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534463 - SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS (2026-01-27),

2. 12486277 - CDK inhibitors and their use as pharmaceuticals (2025-12-02),

3. 12448389 - BRM targeting compounds and associated methods of use (2025-10-21),

4. 11840534 - Substituted tricyclic compounds as FGFR inhibitors (2023-12-12),

5. 11702423 - BRM targeting compounds and associated methods of use (2023-07-18),

6. 11673893 - CDK inhibitors and their use as pharmaceuticals (2023-06-13),

7. 11673883 - Heterocyclic compounds as immunomodulators (2023-06-13),

8. 11667635 - Bicyclic heterocycles as FGFR4 inhibitors (2023-06-06),

9. 11530214 - Bicyclic heterocycles as FGFR inhibitors (2022-12-20),

10. 11053246 - Substituted tricyclic compounds as FGFR inhibitors (2021-07-06),

11. 11014923 - Bicyclic heterocycles as FGFR4 inhibitors (2021-05-25),

12. 10851105 - Bicyclic heterocycles as FGFR4 inhibitors (2020-12-01),

13. 10806785 - Immunomodulator compounds and methods of use (2020-10-20),

14. 10738048 - Bicyclic heterocycles as FGFR4 inhibitors (2020-08-11),

15. 10640503 - Imidazopyridines and imidazopyrazines as LSD1 inhibitors (2020-05-05),

Title: The Innovative Journey of Inventor Liang Lu

Introduction: Liang Lu, a talented inventor based in Hockessin, DE (US), has made significant contributions to the field of technology with his groundbreaking inventions.

Latest Patents: Liang Lu holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a background in engineering and a passion for problem-solving, Liang Lu has successfully developed cutting-edge solutions that have revolutionized various industries. His inventions have not only improved efficiency but have also had a positive impact on society as a whole.

Collaborations: Throughout his career, Liang Lu has collaborated with leading research institutions, universities, and tech companies to further enhance his inventions and bring them to the market. His ability to work in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Liang Lu's dedication to innovation and his relentless pursuit of excellence have established him as a respected figure in the world of inventors. His work continues to inspire future generations to push the boundaries of what is possible through creativity and ingenuity.